ArticleCureus2026
BB8 Technique: An Innovative Approach for Delivering Diluted Belotero® Balance to Treat Infraorbital Hollows.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The infraorbital hollow (IOH) and periorbital skin are among the first areas to show signs of facial aging, but are challenging to treat with hyaluronic acid (HA) fillers because of the thin dermis and scant subcutaneous fat. Cohesive polydensified matrix hyaluronic acid (CPM HA, 22.5 mg/mL HA) Belotero Balance gel (CPM-B) is one of the preferred fillers in this region due to its cohesivity and long-held safety reputation. It is typically injected deep into the orbicularis oculi muscle, but adverse events (AEs), including swelling and the Tyndall effect, can still occur. This retrospective, observational three-patient case series describes and evaluates the efficacy and safety of CPM-B delivered superficially (via the novel BB8 technique) in improving the appearance of IOH. Per the BB8 technique, 1 mL of CPM-B was diluted with 0.8 mL of normal saline to achieve an effective HA concentration of 12.5 mg/mL (dilution ratio 1:0.8) and injected superficially to the subdermal plane of the infraorbital region via a cannula. Patients were photographed before and after treatment and followed up regularly for six to nine months post-treatment. IOH severity was graded using the Merz Aesthetic Scale (MAS), while perceived aesthetic improvements by physicians and patients were assessed using five‑point physician (physician global aesthetic improvement scale (PGAIS)) and subject (subject global aesthetic improvement scale (SGAIS)) global aesthetic improvement ratings (1 = very much improved to 5 = worse). The BB8 technique demonstrated efficacy in improving the appearance of IOH. MAS for IOH improved by one to two grades, with effects lasting for six to nine months, while perceived aesthetic improvement ratings were at least "much improved" at all follow-up visits. No persistent or serious AEs were reported. The BB8 technique is a safe and straightforward method for IOH rejuvenation, allowing injectors to effectively address this delicate and challenging area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.